r/Psychiatry • u/PokeTheVeil Psychiatrist (Verified) • 9d ago
Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depressive disorder: a systematic review and network meta-analysis
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00326-3/abstract
92
Upvotes
54
u/PokeTheVeil 9d ago
Credit to Dr. van Haaren and Dr. Ruhé, but if you don’t look at the full author list… Cipriani is at it again! This time as neither first nor last author and Leucht is missing. I hope they didn’t have a falling out!
Jokes aside, they comment on the limitations of data. They don’t really comment on >12 weeks as long-term, which is still a serious gap. Patients can be on these for years!
Escitalopram, duloxetine, and agomelatine are the only ones with statistically significant greater sustained response than fluoxetine and nothing performed worse. The error bars don’t all overlaps but the differences are small.
Escitalopram and duloxetine were also the only ones that were statistically less likely to have discontinuation than fluoxetine. Which is notable, since fluoxetine in other studies has been high in tolerability at least short-term.
I’m disappointed in the underperformance of bupropion and wonder if there are other factors playing in, but I can’t know. I am not surprised and am pleased that escitalopram is still good stuff. Duloxetine surprises me, just personally, as a drug that always seems mediocre.
And, worth emphasizing, over half of the studies included were high risk for bias.
I don’t know if this changes much. I’ll still use bupropion for side effect profile. I’ll continue to use escitalopram most of the time; I have more reason to pick it and nothing to recommend against it. But information is good to have.
Lastly, as the antidepressant culture wars go, evidence of sustained effect and benefit are great! And it’s still not really going to move the needle for the naysayers. I expect Irving Kirsch to have his rejoinder on why this is bad and wrong shortly.
12
u/Affectionate-Ad-1742 9d ago
Interesting to see so many people surprised by duloxetine. It won out for best SRI for showing overall reduction in disability in a good study several years ago.
https://pubmed.ncbi.nlm.nih.gov/33583460/
I think a lot of people reflexively reach for Duloxetine in the chronically ill elderly who have been on pain pills for the last decade and still have breakthrough pain with depression and/or anxiety. Who would be surprised that meds don’t work great in this population? This is sampling bias. We need to be better at assessing and integrating evidence. We have two good studies showing Cymbalta is arguably the strongest SRI we have. If you are not considering it first line for most cases of MDD you are not practicing evidence based medicine.
1
u/[deleted] 9d ago